| Literature DB >> 19834871 |
F Karakurt1, A Kargili, B Kasapoglu.
Abstract
Pioglitazone is used to improve insulin sensitivity in type 2 diabetes. This group of drugs is usually well tolerated; however, their use may be associated with several adverse effects including edema, weight gain, macular edema and heart failure. Herein we report a patient who developed pancytopenia on the 7th day of oral pioglitazone treatment for the control of diabetes mellitus and fully recovered 6 days after the cessation of this drug. To the best of our knowledge this is the first reported case of pancytopenia induced by pioglitazone therapy. J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart. New York.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19834871 DOI: 10.1055/s-0029-1234065
Source DB: PubMed Journal: Exp Clin Endocrinol Diabetes ISSN: 0947-7349 Impact factor: 2.949